Krystal Biotech, Inc.(KRYS)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Krystal Biotech, Inc. (KRYS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KRYS at 79.2/100 on a 32-signal composite quality model, placing it at rank #43 of 2,960 stocks — the top 5% of the AI-ranked universe. KRYS scores in the top quartile across profitability (98.4), free cash flow (97.0), revenue growth (96.5). Areas of concern include revenue scale (34.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Krystal Biotech, Inc. reports quarterly revenue of $119.2M, net income of $54.8M, an operating margin of 49.0%. Top institutional holders of KRYS by reported 13-F value include FMR, BlackRock, Avoro Capital Advisors, based on the most recent SEC filings. KRYS trades on the Nasdaq exchange and files with the SEC under CIK 1711279. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KRYS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Krystal Biotech, Inc. directly from SEC EDGAR.
AI Quality Score
79.2/100
AI Rank
#43
Revenue
$119.2M
Net Income
$54.8M
Free Cash Flow
$71.2M
Operating Margin
49.0%
KRYS key financials by period
Krystal Biotech, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$389.1M
$204.8M
41.4%
FY 2024
10-K
$290.5M
$89.2M
22.6%
FY 2023
10-K
$50.7M
$10.9M
—
Institutions holding KRYS
Institutional investors reporting a position in Krystal Biotech, Inc. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-03 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
VYJUVEK product revenue rose 24% YoY to $119.2M as Europe ($19.3M) and Japan ($8.3M) launches offset a decline in U.S. sales, lifting net income 43% to $54.8M.
Biggest Revenue Drivers
United States$91.6Mvs $96.0M prior-year quarter
Filing cites a reduction in United States VYJUVEK sales
Europe$19.3M
New market; VYJUVEK launched in Germany August 2025 and France October 2025, with pricing negotiations ongoing
Biggest Revenue Drivers
Total revenue: $119.2M+24% YoY
United States$91.6Mvs $96.0M prior-year quarter
Filing cites a reduction in United States VYJUVEK sales
Europe$19.3M
New market; VYJUVEK launched in Germany August 2025 and France October 2025, with pricing negotiations ongoing
Japan$8.3M
New market; launched October 2025 after pricing negotiations were completed prior to launch
Largest Expense Items
Selling, general and administrative$39.9M+14% YoY
$2.5M higher payroll including stock-based compensation, $1.4M other G&A, $1.0M selling expenses
Research and development$14.5M+1% YoY
$0.8M higher clinical development for KB407, KB707, KB801, KB803, offset by lower B-VEC and KB304 spend
Cost of goods sold$6.4M-10% YoY
Manufacturing process optimizations lowered average cost per unit, partly offset by higher VYJUVEK sales
Margins: Gross margin was 95% for the quarter versus 93% a year earlier, as manufacturing process optimizations lowered average cost per unit. Income from operations rose 48% to $58.4M.
Watch Items from the Filing
Customer concentration: Customer A represents 54% and Customer B 18% of net accounts receivable at June 30, 2026 (66% and 14% at year-end 2025).
U.S. VYJUVEK revenue declined to $91.6M from $96.0M a year earlier, with growth now dependent on newer Europe and Japan markets.
DOJ subpoenas received in Q1 2025 regarding the sponsored genetic testing program for VYJUVEK; the Company cannot estimate any possible loss.
Pricing negotiations continue in Germany into at least 2H 2026 and France into 2027; Italy and Spain launches targeted for 2H 2026.
Accrued rebate reserves grew to $89.4M at June 30, 2026 from $61.9M, with $48.9M of provisions recorded against revenue in six months.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
